论文部分内容阅读
本文旨在探讨EPOCH联合化疗对复发、耐药性淋巴系肿瘤的疗效和毒副作用。在5年中,21例经该方案治疗的复发/耐药患者中数年龄51(15～64)岁,男性17例,女性4例,体能状态中数值为1(范围0～3)。包括急性淋巴细胞白血病(ALL)10例(Ph染色体阳性5例),非霍奇金淋巴瘤(NHL)8例(弥漫性大细胞型3例,弥漫性混合细胞型2例,滤泡性混合细胞型2例,滤泡性中间型1例),成人T细胞白血病淋巴瘤(ATLL)2例,成人T细胞白血病(ATL)1例。均经阿霉素、长春新碱作初期治疗,完
This article aims to explore the efficacy and side effects of EPOCH combined chemotherapy in relapsed and drug-resistant lymphoid tumors. In 5 years, 21 of the relapsed/drug resistant patients treated by this regimen were age 51 (15-64) years old, 17 males and 4 females. The physical status was 1 (range 0-3). Including acute lymphoblastic leukemia (ALL) in 10 cases (Ph chromosome positive in 5 cases), non-Hodgkin’s lymphoma (NHL) in 8 cases (3 cases of diffuse large cell type, diffuse mixed cell type in 2 cases, follicular mixture There were 2 cases of cell type, 1 case of follicular intermediate type, 2 cases of adult T-cell leukemia lymphoma (ATLL), and 1 case of adult T-cell leukemia (ATL). All of them were treated with adriamycin and vincristine for the initial treatment.